Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM595I9)

Drug Name
Omilancor Drug Info
Synonyms
BT-11; 1912399-75-7; A4Y49H6YY8; CHEMBL4788758; Piperazine-1,4-diylbis((6-(1H-benzo[d]imidazol-2-yl)pyridin-2-yl)methanone); Methanone, 1,1'-(1,4-piperazinediyl)bis(1-(6-(1H-benzimidazol-2-yl)-2-pyridinyl)-; [4-[6-(1H-benzimidazol-2-yl)pyridine-2-carbonyl]piperazin-1-yl]-[6-(1H-benzimidazol-2-yl)pyridin-2-yl]methanone; OMILANCOR; BT-11; Omilancor; OMILANCOR [INN]; UNII-A4Y49H6YY8; BT11; SCHEMBL17706588; GTPL10363; BCP32788; BT 11; BT11; Example 1 [US9556146B2]; BDBM50558735; s6419; AKOS037515592; CS-7521; SB18706; HY-102013
Indication
Disease Entry ICD 11 Status REF
Ulcerative colitis DD71 Phase 2 [1]
Cross-matching ID
PubChem CID
121299620
TTD Drug ID
DM595I9

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting LanC-like protein 2 (LANCL2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
LABP-104 DMMYYB9 Rheumatoid arthritis FA20 Phase 1 [3]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
LanC-like protein 2 (LANCL2) TTMK3EX LANC2_HUMAN Agonist [2]

References

1 ClinicalTrials.gov (NCT05057273) A Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Oral BT-11 in Crohn's Disease Patients With Moderate to Severe Disease. U.S.National Institutes of Health.
2 Correction to: Efficacy, Safety, and Tolerability of ?Omilancor in a Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Ulcerative Colitis. Inflamm Bowel Dis. 2022 Dec 1;28(12):1938.
3 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight